Acumen Pharmaceuticals (ABOS) Net Income towards Common Stockholders (2020 - 2026)

Acumen Pharmaceuticals has disclosed Net Income towards Common Stockholders across 7 years of filings, most recently posting -$21.2 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$21.2 million, up 26.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$112.8 million (up 4.31% YoY), and the FY2025 annual result was -$120.6 million, down 16.23% from the prior year.
• Net Income towards Common Stockholders came in at -$21.2 million for Q1 2026 at Acumen Pharmaceuticals, up from -$25.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$9.1 million in Q1 2022 to a low of -$40.8 million in Q2 2025.
• The 5-year median for Net Income towards Common Stockholders is -$15.1 million (2023), against an average of -$20.0 million.
• Across the five-year window, Net Income towards Common Stockholders sank 195.34% in 2022 and surged 33.68% in 2025, its largest moves.
• Acumen Pharmaceuticals' Net Income towards Common Stockholders stood at -$12.9 million in 2022, then declined by 17.58% to -$15.1 million in 2023, then plunged by 149.02% to -$37.6 million in 2024, then soared by 33.68% to -$25.0 million in 2025, then climbed by 15.26% to -$21.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$21.2 million (Q1 2026), -$25.0 million (Q4 2025), and -$25.9 million (Q3 2025), per Business Quant data.